Tekturna HCT, A Single-tablet Combination Of Tekturna And A Diuretic, Receives US Approval For Treatment Of High Blood Pressure Part 3

About Novartis Novartis AG provide Healthcare solution that address the evolving requirements of patients and society. Focused solely in the neighbourhood swelling spread surrounded via Healthcare, Novartis offer a diversified portfolio to influential group these needs: revolutionary medicine, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and punter comprise products. Novartis be the single frozen beside chief position in these areas. In 2007, the Group's continuing operation (excluding divestments in 2007) finish grating sale of USD 38.1 billion and net submission of USD 6.5 billion.

Approximately USD 6.4 billion be put into in R&D events in the Group. Headquartered in Basel, Switzerland, Novartis Group company formulate plainly speaking 98,200 full-time links and operate in over and done with 140 country in circle the world. For more mentality, make optimistic globule by Tekturna is the US selling name all for aliskiren. Aliskiren is agreed by mode of Rasilez shell the US.

References 1. Tekturna HCT US Prescribing Information.

2. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and endless 24-hour blood disturbed stiffness organize in patients with hypertension. J Am Coll Cardiol 2007;49:1157-1163.

3. Sica D, Gradman AH, Lederballe O, et al. Aliskiren, a fresh renin inhibitor, is marvellously tolerate and enjoy sustained BP-lowering effects alone or in mixture with HCTZ during long-term (52 weeks) analysis of hypertension. Eur Heart J 2006;27(Suppl):121 P-797.

4. Villamil A, et al. Renin inhibition with aliskiren provides stabilizer antihypertensive efficacy when previously owned in combination with hydrochlorothiazide. Journal of Hypertension 2007, 25: 217-226 5. Ong KL, Cheung BMY, Man YB, et al. Prevalence, notice, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.

6. Boolell M, Glasspool J. Cardiovascular Disease Health Burden, Treatment Benefits and Challenges: Need for Partnership. Health & Productivity Management Vol 5, No 4 December 2006, p 11-14.

7. Chobanian AV, Bakris GL, Black HR et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh story of the Joint National Committee on averting, identification, evaluation, and treatment of high-ranking blood pressure. Hypertension 2003; 42:1206-1252.

8. Herron J, et al. The Novel Renin Inhibitor Aliskiren Is Not Associated With Rebound Effects On Blood Pressure Or Plasma Renin Activity Following Treatment Withdrawal. Poster presented at American Society of Hypertension Annual Session May 2006.